Monopar Therapeutics

Monopar Therapeutics

Biotechnology • Healthcare • Wilmette, IL, United States • MNPR (NCM)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Raymond James reiterates Outperform rating on Monopar stock amid FDA meeting uncertainty - Investing.com
Investing.com • Jan 7
Is Monopar Therapeutics Inc. (NASDAQ:MNPR) Trading At A 46% Discount? - Yahoo Finance
Yahoo Finance • Nov 22
Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout. Here's Why. - Investor's Business Daily
Investor's Business Daily • Sep 15
Independent Director Arthur Klausner Sold A Bunch Of Shares In Monopar Therapeutics - simplywall.st
simplywall.st • Dec 21
Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Wall Street Zen - MarketBeat
MarketBeat • Dec 14

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Monopar Therapeutics had layoffs?
No layoff events have been recorded for Monopar Therapeutics in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Monopar Therapeutics have?
Monopar Therapeutics has approximately 14 employees.
What industry is Monopar Therapeutics in?
Monopar Therapeutics operates in the Biotechnology industry, within the Healthcare sector.
Is Monopar Therapeutics a publicly traded company?
Yes, Monopar Therapeutics is publicly traded under the ticker symbol MNPR on the NCM. The company has a market capitalization of approximately $0.47 billion.
Where is Monopar Therapeutics headquartered?
Monopar Therapeutics is headquartered in Wilmette, IL, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.